Biotech Values

[Double_Bagel]

So consensus was

$236 US and $32 Ex-US

Instead, we got

$138 US and $93 Ex-US

There is good news and bad news in this. The good news is that ENTA gets a higher share from the much higher Ex-US sales. But the bad news is that it won't offset the lower revenues from the US sales.

But I am encouraged by the Ex-US sales. Maybe, from ENTA's viewpoint it doesn't need ABBV to end the year with a $3Billion run rate as long as Ex-US sales comes in much higher in each of the remaining 3 quarters.